Allergic rhinitis (AR), commonly known as hay fever, is a chronic inflammation of the nasal cavity caused by inhaling airborne allergens, such as pollen, dust, mold, and weeds. This can trigger sneezing, nasal congestion, itchy nose and irritation of the throat, mouth, and eyes. In the United States, it affects 40 to 60 million individuals. The prevalence of AR has increased over the last several decades and this trend is expected to continue.
The only disease modifying therapy which currently available to patients is allergen specific immunotherapy (AIT). AIT is a targeted treatment consisting of a small amount of allergen extract given sublingually or subcutaneously over the course of a few years. AIT requires long-term commitment (3 to 5 years), resulting in low patient adherence and high patient costs.
At Inimmune we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that binds and activates Toll-like receptor 4. When delivered intranasally, INI-2004 dramatically reduced measures of AR in pre-clinical animal models. These include airway resistance, eosinophil influx, and the production of cytokines indicative of an allergic response. Phase I clinical studies will begin in Q2 2023. Demonstration of safety and efficacy in people will lead to a first-in-class, disease-modifying treatment for AR that may be used for any allergen, potentially changing how AR is treated worldwide.
TLR-7/8 (INI-4001), TLR-4 (INI-2002), CTLR (UM-1098), STING
Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.
Professional doctor or nurse giving flu or COVID-19 injection to patient. Woman in medical face mask getting antiviral vaccine at hospital or health center during vaccination and immunization campaign.